Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term study of TS-172 in hyperphosphatemia patients on hemodialysis with phosphate binders
jRCT2031250523Phase 3Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of TS-172 in hyperphosphatemia (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Adverse events. Started Dec 2025; status: recruiting.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on jRCT2031250523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250523.